

# Jo Caers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3915996/publications.pdf>

Version: 2024-02-01

73  
papers

6,269  
citations

218592

26  
h-index

106281

65  
g-index

74  
all docs

74  
docs citations

74  
times ranked

7941  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serological response to SARS-CoV-2 mRNA-containing lipid nanoparticle vaccine in patients with multiple myeloma: A negative impact of CD38 regulatory T cells?. British Journal of Haematology, 2022, .	1.2	0
2	Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer Journal, 2022, 12, 45.	2.8	57
3	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 2022, 139, 2747-2757.	0.6	16
4	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. British Journal of Haematology, 2021, 194, 496-507.	1.2	67
5	Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 2021, 56, 2672-2681.	1.3	16
6	Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma. Cancers, 2021, 13, 3072.	1.7	5
7	2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica, 2021, 106, 2799-2812.	1.7	22
8	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. Journal of Clinical Epidemiology, 2021, 137, 31-44.	2.4	11
9	A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 183.	6.9	12
10	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer Journal, 2021, 11, 192.	2.8	62
11	Altered chondrocyte differentiation, matrix mineralization and MEK-Erk1/2 signaling in an INPPL1 catalytic knock-out mouse model of opsismodysplasia. Advances in Biological Regulation, 2020, 76, 100651.	1.4	6
12	The Road to a Cure: Emerging Treatments for Multiple Myeloma. Cancers, 2020, 12, 3593.	1.7	0
13	Recommendations on the management of multiple myeloma in 2020. Acta Clinica Belgica, 2020, , 1-17.	0.5	1
14	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of Hematology and Oncology, 2020, 13, 173.	6.9	91
15	Mass cytometry in POEMS (polyneuropathy, organomegaly, endocrinopathy, M $\alpha$ C protein, skin changes) syndrome: looking for a needle in a haystack. British Journal of Haematology, 2020, 190, 16-17.	1.2	11
16	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 2020, 112, 141-146.	0.7	2
17	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Leukemia, 2020, 34, 2451-2459.	3.3	14
18	The anti-mitotic agents PTC028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene. British Journal of Haematology, 2020, 190, 877-890.	1.2	15

#	ARTICLE	IF	CITATIONS
19	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 762.	2.2	57
20	Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 11.	2.2	42
21	Loss of Stromal Galectin-1 Enhances Multiple Myeloma Development: Emphasis on a Role in Osteoclasts. <i>Cancers</i> , 2019, 11, 261.	1.7	11
22	Dualâ€œtracer PET/CT scan after injection of combined [ <sup>18</sup> F]NaF and [ <sup>18</sup> F]FDG outperforms MRI in the detection of myeloma lesions. <i>Hematological Oncology</i> , 2019, 37, 193-201.	0.8	7
23	Molecular mechanisms, current management and next generation therapy in myeloma bone disease. <i>Leukemia and Lymphoma</i> , 2018, 59, 14-28.	0.6	17
24	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	1.7	110
25	Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma. <i>Haematologica</i> , 2018, 103, 325-335.	1.7	23
26	Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. <i>Blood Cancer Journal</i> , 2018, 8, 105.	2.8	113
27	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
28	Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease. <i>Haematologica</i> , 2018, 103, 1359-1368.	1.7	14
29	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. <i>Journal of Hematology and Oncology</i> , 2018, 11, 10.	6.9	181
30	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
31	Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development. <i>Blood</i> , 2018, 132, 4484-4484.	0.6	3
32	Genomic studies of multiple myeloma reveal an association between X chromosome alterations and genomic profile complexity. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 18-27.	1.5	2
33	Exome copy number variation detection: Use of a pool of unrelated healthy tissue as reference sample. <i>Genetic Epidemiology</i> , 2017, 41, 35-40.	0.6	0
34	A First Report on [ <sup>18</sup> F]FPRGD <sub>2</sub> PET/CT Imaging in Multiple Myeloma. <i>Contrast Media and Molecular Imaging</i> , 2017, 2017, 1-7.	0.4	4
35	Central nervous system involvement by multiple myeloma: A multiâ€œinstitutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
36	Autotransplants in older multiple myeloma patients: hype or hope in the era of novel agents?. <i>Haematologica</i> , 2016, 101, 1276-1278.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
38	Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. <i>Journal of Hematology and Oncology</i> , 2016, 9, 53.	6.9	33
39	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	1.9	28
40	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
41	Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma. <i>Blood</i> , 2016, 128, 309-309.	0.6	2
42	SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30712-30729.	0.8	19
43	Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma. <i>Oncotarget</i> , 2016, 7, 37931-37943.	0.8	78
44	Immunomodulatory Effects of the <i>Agaricus blazei</i> Murrill-Based Mushroom Extract AndoSan in Patients with Multiple Myeloma Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation: A Randomized, Double Blinded Clinical Study. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	44
45	Galectin expression in cancer diagnosis and prognosis: A systematic review. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 235-247.	3.3	188
46	Impact of the immunomodulating peptide thymosin alpha 1 on multiple myeloma and immune recovery after hematopoietic stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 989-998.	2.0	2
47	Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide. <i>European Journal of Haematology</i> , 2014, 92, 179-180.	1.1	3
48	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
49	The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. <i>Haematologica</i> , 2014, 99, 629-637.	1.7	61
50	Establishment of a Murine Graft-versus-Myeloma Model Using Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2014, 9, e113764.	1.1	11
51	Bone mass of the calvarium. <i>Skeletal Radiology</i> , 2013, 42, 1157-1159.	1.2	1
52	Bone mass of the calvarium. <i>Skeletal Radiology</i> , 2013, 42, 1185-1187.	1.2	0
53	Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. <i>Annals of Medicine</i> , 2013, 45, 413-422.	1.5	11
54	A novel mutation in the CLUB sequence of matriptase-2 ( <i>TMPRSS6</i> ) is implicated in iron-resistant iron deficiency anaemia (IRIDA). <i>British Journal of Haematology</i> , 2013, 160, 564-565.	1.2	17

#	ARTICLE	IF	CITATIONS
55	Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors. <i>PLoS ONE</i> , 2013, 8, e62818.	1.1	17
56	Panhypopituitarism and diabetes insipidus in a patient with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 2515-2516.	0.6	4
57	A Novel Mouse Model for Multiple Myeloma (MOPC315.BM) That Allows Noninvasive Spatiotemporal Detection of Osteolytic Disease. <i>PLoS ONE</i> , 2012, 7, e51892.	1.1	61
58	Biological aspects of angiogenesis in multiple myeloma. <i>International Journal of Hematology</i> , 2011, 94, 505-518.	0.7	26
59	Thymosin $\alpha$ 4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma. <i>Haematologica</i> , 2010, 95, 163-167.	1.7	22
60	Diffuse xanthomatosis as a presenting feature of multiple myeloma. <i>European Journal of Haematology</i> , 2010, 84, 460-461.	1.1	3
61	Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 379-381.	1.2	27
62	Thymosin $\alpha$ 4 in multiple myeloma: friend or foe. <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 125-129.	1.8	8
63	The Effects of Forodesine in Murine and Human Multiple Myeloma Cells. <i>Advances in Hematology</i> , 2010, 2010, 1-8.	0.6	4
64	Multiple myeloma – an update on diagnosis and treatment. <i>European Journal of Haematology</i> , 2008, 81, 329-343.	1.1	46
65	Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. <i>Bulletin Du Cancer</i> , 2008, 95, 301-13.	0.6	27
66	Decreased Thymosin Beta 4 Expression Results in Poor Prognosis and Decreased Survival in Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1703-1703.	0.6	0
67	Ac-SDKP: Linking cardiac remodeling to hematological malignancies. <i>Leukemia and Lymphoma</i> , 2006, 47, 1732-1733.	0.6	0
68	Acute interstitial nephritis associated with salmonellosis. <i>European Journal of Internal Medicine</i> , 2006, 17, 217-219.	1.0	3
69	Bone Marrow Adipocytes Influence Multiple Myeloma Development by Secretion of Different Growth Factors and Chemokines.. <i>Blood</i> , 2006, 108, 5030-5030.	0.6	0
70	The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. <i>British Journal of Haematology</i> , 2005, 132, 051220022257013.	1.2	37
71	Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. <i>Supportive Care in Cancer</i> , 2005, 13, 325-331.	1.0	162
72	Of mice and men: disease models of multiple myeloma. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 373-380.	1.2	6

#	ARTICLE	IF	CITATIONS
73	Radiotheranostic Agents in Hematological Malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5